Background: Immune‐checkpoint inhibitor (ICI) therapy elicits durable responses in a subset of patients with advanced melanoma. However, the appropriate timing for treatment cessation remains an unresolved issue. Moreover, some patients are required to discontinue therapy due to the occurrence of severe adverse events. Upon treatment cessation, a subset of patients maintains a durable response, while some patients relapse and require rechallenge with ICI. Criteria for a safe stop of ICI have not been established. Objectives: The aim of this systematic review and meta‐analysis was to evaluate the durability of response in melanoma patients who discontinued ICI therapy. Furthermore, the outcome of patients who electively stopped therapy was compared to that of patients who discontinued therapy due to adverse events. Methods: MEDLINE/PubMed, Embase and the Cochrane Library were searched for studies reporting outcomes after ICI discontinuation in patients with advanced melanoma. Pooled 1‐ to 3‐year progression‐free survival (PFS) and overall survival (OS) rates were estimated using random‐effects models. The impact of the reason for treatment discontinuation, therapy regime and treatment duration on relapse‐free survival was evaluated. Results: Twenty studies including 1832 patients were analysed. The pooled 1‐ and 3‐year PFS rates after therapy stop were 86% (95% CI 80%–91%) and 71% (95% CI 64%–77%). A significantly higher 1‐year PFS rate was observed in patients who electively discontinued treatment in contrast to toxicity‐related therapy cessation (91% vs. 79%). Longer ICI treatment was associated with a higher PFS rate. 1‐ and 3‐year OS rates post ICI treatment discontinuation were 96% (95% CI 91%–99%) and 86% (95% CI 79%–92%). Conclusions: Most patients remained relapse‐free after ICI treatment. Patients with a treatment duration of at least 2 years are ideal candidates for treatment cessation, while treatment discontinuation may be considered after at least 1 year of ICI. PROSPERO number: CRD42024543781.
5 May 2022 in Journal of the European Academy of Dermatology and Venereology
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases, with an increasing number of targeted therapies available. While biologics to treat AD exclusively target the key cytokines of type 2 immunity, Janus kinase inhibitors target a broad variety of cytokines, including IFN-γ. To better stratify patients for optimal treatment outcomes, the identification and characterization of subgroups, especially with regard to their IFNG expression, is of great relevance, as the role of IFNG in AD has not yet been fully clarified. This study aims to define AD subgroups based on their lesional IFNG expression and to characterize them based on their gene expression, T cell secretome and clinical attributes. RNA from the lesional and non-lesional biopsies of 48 AD patients was analyzed by RNA sequencing. Based on IFNG gene expression and the release of IFN-γ by lesional T cells, this cohort was categorized into three IFNG groups (high, medium, and low) using unsupervised clustering. The low IFNG group showed features of extrinsic AD with a higher prevalence of atopic comorbidities and impaired epidermal lipid synthesis. In contrast, patients in the high IFNG group had a higher average age and an activation of additional pro-inflammatory pathways. On the cellular level, higher amounts of M1 macrophages and natural killer cell signaling were detected in the high IFNG group compared to the low IFNG group by a deconvolution algorithm. However, both groups shared a common dupilumab response gene signature, indicating that type 2 immunity is the dominant immune shift in both subgroups. In summary, high and low IFNG subgroups correspond to intrinsic and extrinsic AD classifications and might be considered in the future for evaluating therapeutic efficacy or non-responders.
19 August 2025 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Summary: Bowen's disease (BD) is an intraepidermal malignancy that may progress to skin cancer, yet no study has compared interventions from randomized controlled trials (RCT). We synthesized RCT data to calculate lesion‐specific initial clearance rates, long‐term clearance rates, and cosmetic outcomes relative to placebo. We searched MEDLINE, EMBASE, CENTRAL and trial registers up to September 30, 2024, and included nine studies (672 patients, 844 lesions). Interventions compared to placebo and ranked via network meta‐analysis included surgery, imiquimod, photodynamic therapy (PDT), laser ablation (LA), laser‐assisted PDT (LA‐PDT), cryotherapy and 5‐fluoruracil (5‐FU). Bias was assessed using the revised Cochrane risk‐of‐bias tool. The study was registered in PROSPERO prior to data extraction (CRD42024583966). All interventions showed higher lesion‐specific clearance rates than placebo. Regarding initial clearance, LA‐PDT ranked first, followed by surgery and LA. Surgery ranked first for long‐term clearance, followed by LA‐PDT and PDT. Cryotherapy and imiquimod ranked lowest for initial clearance and long‐term clearance. PDT, LA‐PDT, and 5‐FU showed the best cosmetic outcome, while surgery had the worst. Limitations included moderate to high bias and study heterogeneity. Our findings support clinical decision‐making for BD, identifying LA‐PDT and PDT as effective options balancing efficacy and cosmetic results, and surgery as optimal for long‐term clearance.
17 January 2026 in International Journal of Dermatology
Kidney transplant recipients (KTRs) are at increased risk of developing cutaneous squamous cell carcinoma (cSCC), particularly when treated with calcineurin inhibitors (CNI), which are strongly associated with tumorigenesis. In contrast, mTOR inhibitors such as sirolimus have demonstrated antitumor activity, but their role in secondary prevention of cSCC remains unclear. We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) to evaluate the impact of switching from a CNI‐based to an mTOR inhibitor‐based immunosuppressive regimen on the incidence of cSCC in KTRs with prior cSCC. MEDLINE, EMBASE, CENTRAL, and trial registries were searched through June 2025. Incidence rate ratios (IRRs) for cSCC and risk ratios (RRs) for adverse events (AEs) were pooled using a random‐effects model. Risk of bias was assessed with Cochrane RoB2. The study was registered in PROSPERO prior to data extraction (CRD42024583966). The study was unfunded. Four RCTs (393 patients) were included. Sirolimus significantly reduced 2‐year cSCC incidence (IRR 0.51, 95% CI 0.39–0.67). However, discontinuation was more frequent (RR 8.60, 95% CI 1.95–37.93) due to AEs. No significant differences in mortality or graft rejection were found. Certainty of evidence was high for cSCC incidence and low for adverse events due to heterogeneity and selective reporting. In conclusion, sirolimus reduces secondary cSCC risk but increases AEs; patient selection and monitoring are essential. Trial Registration: PROSPERO number: CRD42024583966
Background: Melanoma staging at diagnosis predominantly depends on the tumor thickness. Sentinel lymph node biopsy (SLNB) is a common tool for primary staging. However, for tumors of >4 mm with ulceration, 3D whole-body imaging and, in particular, Fluor-18-Deoxyglucose positron emission tomography combined with computed tomography (18F-FDG-PET/CT), is recommended beforehand. This study aimed to investigate the real-world data of whole-body imaging for initial melanoma staging and its impact on the subsequent diagnostic and therapeutic procedures. Methods: In this retrospective single-center study, 94 patients receiving 18F-FDG-PET/CT and six patients with whole-body computed tomography (CT) scans were included. The clinical characteristics, imaging results, and histologic parameters of the primary tumors and metastases were analyzed. Results: Besides the patients with primary tumors characterized as pT4b (63%), the patients with pT4a tumors and pT3 tumors close to 4 mm in tumor thickness also received initial whole-body imaging. In 42.6% of the patients undergoing 18F-FDG-PET/CT, the imaging results led to a change in the diagnostic or therapeutic procedure following on from this. In 29% of cases, sentinel lymph node biopsy was no longer necessary. The sensitivity and specificity of 18F-FDG-PET/CT were 66.0% and 93.0%, respectively. Conclusion: Whole-body imaging as a primary diagnostic tool is highly valuable and influences the subsequent diagnostic and therapeutic procedures in a considerable number of patients with a relatively high tumor thickness. It can help avoid the costs and invasiveness of redundant SLNB and simultaneously hasten the staging of patients at the time of diagnosis.